Paper Details

  1. Home
  2. Paper Details

Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.

Author: BejarC, Kirschbaum-SlagerN, LazaroviciP, ShohamS, WeinstockM, YoudimM B

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

TV3326 is a new drug that combines the neuroprotective properties of rasagiline, which inhibits MAO-B, and the cholinesterase (ChE) inhibitory activity of rivastigmine. This study investigates the neuroprotective effects of TV3326 in lab and living models. TV3326 protected nerve cells from damage in lab studies, and in mice, a single injection reduced brain swelling and improved motor function and memory after head injury. In rats, TV3326 reduced nerve cell damage and improved memory after injury induced by streptozotocin. The neuroprotective effect in lab-grown cells may be due to a combination of ChE inhibition and anti-apoptotic activity, with the latter associated with the presence of the propargyl group.
Paper Details　
Original Abstract of the Article :
TV3326, (N-propargyl-(3R)-aminoindan-5-yl-ethyl,methyl carbamate) was prepared in order to combine the neuroprotective effects of rasagiline, a selective inhibitor of monoamine oxidase (MAO)-B with the cholinesterase (ChE) inhibitory activity of rivastigmine as a potential treatment for Alzheimer's ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1749-6632.2001.tb03622.x

データ提供：米国国立医学図書館（NLM）

Neuroprotective Effects of Novel Cholinesterase Inhibitors: A New Oasis for Alzheimer's Disease

Alzheimer's disease is a devastating neurological condition, creating a barren landscape for cognitive function. This study explores the potential of a novel cholinesterase inhibitor, TV3326, as a treatment for Alzheimer's disease. It combines the neuroprotective properties of rasagiline with the cholinesterase-inhibiting activity of rivastigmine. The study, like a meticulous exploration of the desert for hidden oases, investigates the neuroprotective effects of TV3326 in both in vitro and in vivo models. The findings suggest that TV3326 has potential as a neuroprotective agent, offering a possible oasis for those living with Alzheimer's disease.

A Glimpse of Hope in the Desert of Alzheimer's Disease

This study, like a refreshing spring in the desert, provides a glimmer of hope for those struggling with Alzheimer's disease. The findings suggest that TV3326 has the potential to mitigate the damaging effects of the disease, offering a possible path toward improved cognitive function.

Navigating the Desert of Cognitive Decline

This research underscores the importance of continued research to find effective treatments for Alzheimer's disease. It also highlights the need for early detection and intervention to minimize the long-term impact of this devastating condition. It is important to discuss treatment options with a healthcare professional to determine the best course of action for individual patients.

Dr.Camel's Conclusion

This study, like a compass in the desert, provides a promising direction for Alzheimer's disease research. It highlights the potential of TV3326 as a neuroprotective agent and underscores the need for continued research to find effective treatments for this challenging disease.

Date :
  1. Date Completed 2001-08-09
  2. Date Revised 2019-06-16
Further Info :

Pubmed ID

11462767

DOI: Digital Object Identifier

10.1111/j.1749-6632.2001.tb03622.x

Related Literature

Article Analysis
・Effects of rasagiline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.